双作用肥胖药物重塑大脑食欲回路。
Dual-action obesity drug rewires brain circuits for appetite.
作者信息
Cook Tyler M, Sandoval Darleen
出版信息
Nature. 2024 May;629(8014):1011-1012. doi: 10.1038/d41586-024-01352-6.
Abstract
A two-in-one drug that modulates neural pathways involved in appetite and reward might prove to be more effective and longer lasting than current weight-loss drugs on the market.
摘要
一种能调节与食欲和奖赏有关的神经通路的二合一药物，可能比市面上现有的减肥药物更有效且效果更持久。
相似文献
1
Dual-action obesity drug rewires brain circuits for appetite.双作用肥胖药物重塑大脑食欲回路。
Nature. 2024 May;629(8014):1011-1012. doi: 10.1038/d41586-024-01352-6.
2
Pharmacology of appetite suppression: implication for the treatment of obesity.食欲抑制的药理学：对肥胖治疗的意义。
Curr Drug Targets. 2001 Dec;2(4):353-70. doi: 10.2174/1389450013348209.
3
The gut yields clues to obesity, therapies.肠道为肥胖及治疗提供线索。
JAMA. 2005 May 11;293(18):2200-1. doi: 10.1001/jama.293.18.2200.
4
Regulation of appetite to treat obesity.食欲调节治疗肥胖。
Expert Rev Clin Pharmacol. 2011 Mar;4(2):243-59. doi: 10.1586/ecp.11.3.
5
Models and strategies in the development of antiobesity drugs.抗肥胖药物研发中的模型与策略
Vet Pathol. 2014 May;51(3):695-706. doi: 10.1177/0300985813492801. Epub 2013 Jul 16.
6
Pharmacotherapy of obesity: emerging drugs and targets.肥胖症的药物治疗：新兴药物与靶点
Expert Opin Ther Targets. 2009 Feb;13(2):195-207. doi: 10.1517/14728220802637063.
7
Novel pharmacotherapies for obesity poised to enter market.新型肥胖症药物疗法即将上市。
Nat Rev Drug Discov. 2009 Nov;8(11):833-4. doi: 10.1038/nrd3044.
8
Lorcaserin--not a new weapon in the battle with appetite.氯卡色林——并非对抗食欲的新武器。
Nat Rev Endocrinol. 2010 Dec;6(12):663-4. doi: 10.1038/nrendo.2010.193.
9
Obesity pharmacotherapy: what is next?肥胖症药物治疗：下一步是什么？
Mol Aspects Med. 2013 Feb;34(1):71-83. doi: 10.1016/j.mam.2012.10.005. Epub 2012 Oct 24.
10
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].[医学前沿；新型抗肥胖药物的前景]
Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):753-9. doi: 10.2169/naika.103.753.
本文引用的文献
1
GLP-1-directed NMDA receptor antagonism for obesity treatment.GLP-1 靶向 NMDA 受体拮抗剂治疗肥胖。
Nature. 2024 May;629(8014):1133-1141. doi: 10.1038/s41586-024-07419-8. Epub 2024 May 15.
2
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.停用司美格鲁肽后的体重反弹和心脏代谢影响：STEP 1 试验延伸。
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19.
3
Energy compensation and metabolic adaptation: "The Biggest Loser" study reinterpreted.能量补偿和代谢适应：重新解读《减肥达人》研究
Obesity (Silver Spring). 2022 Jan;30(1):11-13. doi: 10.1002/oby.23308. Epub 2021 Nov 23.
4
Semaglutide lowers body weight in rodents via distributed neural pathways.司美格鲁肽通过分布式神经通路降低啮齿动物的体重。
JCI Insight. 2020 Mar 26;5(6):133429. doi: 10.1172/jci.insight.133429.
5
Dopamine and diet-induced obesity.多巴胺与饮食诱导的肥胖
Nat Neurosci. 2019 Jan;22(1):1-2. doi: 10.1038/s41593-018-0304-0.
6
Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.与体重指数相关的蛋白变异体提示了控制能量摄入和消耗的途径在肥胖中的作用。
Nat Genet. 2018 Jan;50(1):26-41. doi: 10.1038/s41588-017-0011-x. Epub 2017 Dec 22.
7
Comparison of the effects of the acute administration of dexoxadrol, levoxadrol, MK-801 and phencyclidine on body temperature in the rat.右吗拉胺、左吗拉胺、MK-801及苯环利定急性给药对大鼠体温影响的比较。
Neuropharmacology. 1989 Aug;28(8):829-35. doi: 10.1016/0028-3908(89)90175-5.
Zotero 插件